MP32-12 INCIDENCE OF DE NOVO PROSTATE CANCER IN RENAL TRANSPLANT RECIPIENTS

Abstract

You have accessJournal of UrologyTransplantation & Vascular Surgery: Renal Transplantation & Vascular Surgery II1 Apr 2016MP32-12 INCIDENCE OF DE NOVO PROSTATE CANCER IN RENAL TRANSPLANT RECIPIENTS Benjamin Sherer, Karl Godlewski, and Leslie Deane Benjamin ShererBenjamin Sherer More articles by this author , Karl GodlewskiKarl Godlewski More articles by this author , and Leslie DeaneLeslie Deane More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1307AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Compared to age-matched controls in the general population, renal transplant recipients (RTRs) are at an increased risk for a variety of malignancies. We sought to determine if RTRs have an increased incidence of prostate cancer (CaP) compared to age matched members of the general population. METHODS We performed a comprehensive literature review utilizing a pre-determined search strategy including the terms prostate cancer, renal transplantation, immunosuppression, malignancy, and incidence. Studies with >1000 male RTRs published within the past 10 years with at least 5 years of follow up were included for meta-analysis. Standardized incidence ratios (SIR) compared to the general population (matched for age, gender, and time period) were evaluated for each study. We then determined an overall SIR of CaP in RTRs of the combined cohort (calculated with exact Poisson 95% confidence interval). RESULTS Five studies met inclusion criteria and, in total, included 31,288 male RTRs treated at >20 transplant centers throughout the world (England, Italy, Hong Kong, Australia, New Zealand) since 1972. Among individual studies, reported SIRs of CaP in RTRs ranged from 0.88 (0.39-1.95) to 1.7 (1.2-2.3). In the combined cohort, at median follow up of 11.6 years after renal transplantation, there were 213 reported cases of de novo CaP. The expected number of age-adjusted CaP cases in the combined study populations was 183.7. Combined analysis revealed a SIR of CaP in RTRs of 1.16 (95% CI 0.85-1.5). CONCLUSIONS RTRs do not appear to be at a significantly increased risk of de novo CaP compared to age-matched men in the general population. More contemporary data reflecting current immunosuppression regimens (more routine use of mTOR inhibitors) and longer follow up is necessary to better delineate any increased risk of CaP in RTRs. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e432 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Benjamin Sherer More articles by this author Karl Godlewski More articles by this author Leslie Deane More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...